Compare AbbVie Inc (ABBV) vs Accenture plc (ACN) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Accenture (ACN) trades at $179.82, up 2.33% in the last session, with a bullish technical outlook and strong fundamental performance. The stock exhibits robust revenue growth, with 2025 revenue reaching $69.67 billion and net income of $7.68 billion, supported by consistent earnings beats. Recent partnerships with TEPCO Solution Advance and AlphaSense highlight strategic AI initiatives, enhancing its consulting and digital transformation services.

The investment outlook is positive, driven by solid financials, a consensus price target of $189.77, and low debt. Risks include competitive pressures and macroeconomic sensitivity. Analyst sentiment is strongly bullish with 66% buy ratings, indicating confidence in continued growth and shareholder value creation.